About half of the physicians who participate in clinical trials do only one trial, never doing another one. About half of the investigators in clinical trials are new, doing their first, and possibly last, clinical trial. Doctors do not do second trials because of the extra work and time needed to conduct a trial and … Read more
In a new guidance released this week FDA revised the CTD and eCTD formats of market approval applications for drugs and biologics (NDA, ANDA and BLA) with the intent to simplify the documents and provide higher flexibility for organizing content. FDA also withdrew two previous guidance documents that described detailed granularity instructions giving excruciating details … Read more
California passed a law this week that requires physicians providing unapproved stem cell therapies to prominently display at multiple locations within the clinic that the stem cell therapy provided by them is not approved by FDA. The intent of the new law is to assure that patients are aware of the unapproved status of the … Read more
Of the 55,000 subjects who participated in cancer clinical trials between 2003 and 2016, only 6% were African-Americans, 5% were Asians, and 3% were Hispanics, creating an abysmal minority representation in the data that formed the basis of FDA approval. There are no legal ways for FDA to push sponsors to increase minority representation in … Read more
Last week at a conference on real world evidence (RWE) organized by the National Academy of Sciences in Washington DC, the FDA Commissioner, Dr. Gottlieb, and The CDER chief, Dr. Woodcock, emphasized the limitation of conventional clinical trials and the importance of RWE, promising new guidance documents and new regulatory paradigms to increase the use … Read more
This week FDA issued 13 Warning Letters to online pharmacies selling prescription drugs without prescription, drugs long taken off the US market for safety reasons, and selling drugs that were never approved in the US. These Warning Letters cite hundreds of websites, mostly hosted from outside the US. It does not seem like FDA’s action … Read more
Can FDA be forced to recognize un-proven stem cell therapies due to pressure from States? Will the state laws curtail development of FDA-approved stem cell therapies? A stem cell clinic is one that offers a product containing enriched stem cell preparations to patients for treating a variety of indications. This month a new law came … Read more
It has been argued that because expedited approval pathways allow drugs to be approved with incomplete analysis of safety and efficacy, it potentially leads to new drugs with limited benefit and/or with potential safety concerns. But this is a simplistic one sided argument that does not address the context in which such drugs are approved. … Read more
Why are drugs expensive; is it because the cost of developing new drugs is very high, or that there are onerous regulatory processes for market approval, or may be it takes too long to develop a new drug? And if all these were addressed would it lead to cheaper drugs? This week the FDA Commissioner … Read more
Real World Evidence (RWE) and Real World Data (RWD) are very important but distinct aspects of the clinical use information available for a drug. The 21st Century Cures Act mandates FDA to use RWE in support of the approval of a product and FDA’s opinion about the utility of such data in support of market … Read more
